Dcp1a Antibody (Rabbit mAb) [C9H17]

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 - 1:10000 IHC1:250 IF1:250 FCM1:150

Application
WB, IHC, IF, FCM

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
63 kDa 75 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Dcp1a Antibody (Rabbit mAb) [C9H17] detects endogenous levels of total Dcp1a protein.

Clone
C9H17

Synonym(s)
SMIF, DCP1A, mRNA-decapping enzyme 1A, Smad4-interacting transcriptional co-activator, Transcription factor SMIF

Background
Dcp1a (mRNA-decapping enzyme 1A) is a member of the DCP1 family that functions as a central cofactor in the eukaryotic mRNA decapping complex, coupling recognition of the 7‑methyl guanosine cap to its hydrolysis and thereby controlling both basal mRNA turnover and nonsense-mediated mRNA decay. The protein contains an N‑terminal EVH1-like domain that binds proline-rich sequences and a C‑terminal regulatory region that engages other decapping factors, together forming a scaffold that positions Dcp2, cap-binding proteins and NMD components for efficient decapping. Within the decapping complex, Dcp1a enhances Dcp2’s affinity for mRNA caps and is essential for assembling a functional decapping holoenzyme and for linking the complex to cap-binding proteins, which allows it to process both ARE-containing transcripts and general mRNA populations. Interaction with the NMD adaptor PNRC2 is structurally defined by binding of the PNRC2 proline-rich region to the EVH1 domain of Dcp1a, while an NR box in PNRC2 connects to hyperphosphorylated Upf1; this tripartite arrangement bridges the surveillance machinery and the decapping complex, recruits Dcp1a to premature termination codon–containing transcripts and stimulates Dcp2 activity to accelerate NMD-specific cap removal. Disruption of the PNRC2–Dcp1a interface abolishes PNRC2 localization to P‑bodies and its ability to promote mRNA degradation when tethered to reporter mRNAs, indicating that Dcp1a provides a critical docking surface that couples NMD adaptors to the catalytic decapping core and supports P‑body assembly. Dcp1a and Dcp1b carry non‑redundant roles: Dcp1a is required for decapping complex assembly and for interactions with cap-binding proteins and cofactors that shape transcript “buffering,” while Dcp1b plays more specialized roles in tuning subsets of transcripts, underscoring the centrality of Dcp1a in global mRNA decay control. In oocyte maturation and early embryogenesis, maternally recruited Dcp1a and Dcp2 are synthesized from maternal mRNAs via cytoplasmic polyadenylation, phosphorylated, and used to drive large-scale degradation of maternal transcripts; interfering with Dcp1a/Dcp2 accumulation by RNAi or morpholinos reduces maternal mRNA clearance and impairs activation of the zygotic genome, demonstrating that Dcp1a-mediated decapping is essential for the transition from mRNA stability to instability and for successful oocyte-to-zygote conversion. Dcp1a also participates in signal transduction: its amino-terminal domain can activate protein kinase R (PKR), inducing translational arrest and linking mRNA decay factors to stress-response pathways, and it contributes to TGF‑β1–dependent transcriptional responses by supporting transactivation of target genes after TGFB1 stimulation.

Background

Dcp1a (mRNA-decapping enzyme 1A) is a member of the DCP1 family that functions as a central cofactor in the eukaryotic mRNA decapping complex, coupling recognition of the 7‑methyl guanosine cap to its hydrolysis and thereby controlling both basal mRNA turnover and nonsense-mediated mRNA decay. The protein contains an N‑terminal EVH1-like domain that binds proline-rich sequences and a C‑terminal regulatory region that engages other decapping factors, together forming a scaffold that positions Dcp2, cap-binding proteins and NMD components for efficient decapping. Within the decapping complex, Dcp1a enhances Dcp2’s affinity for mRNA caps and is essential for assembling a functional decapping holoenzyme and for linking the complex to cap-binding proteins, which allows it to process both ARE-containing transcripts and general mRNA populations. Interaction with the NMD adaptor PNRC2 is structurally defined by binding of the PNRC2 proline-rich region to the EVH1 domain of Dcp1a, while an NR box in PNRC2 connects to hyperphosphorylated Upf1; this tripartite arrangement bridges the surveillance machinery and the decapping complex, recruits Dcp1a to premature termination codon–containing transcripts and stimulates Dcp2 activity to accelerate NMD-specific cap removal. Disruption of the PNRC2–Dcp1a interface abolishes PNRC2 localization to P‑bodies and its ability to promote mRNA degradation when tethered to reporter mRNAs, indicating that Dcp1a provides a critical docking surface that couples NMD adaptors to the catalytic decapping core and supports P‑body assembly. Dcp1a and Dcp1b carry non‑redundant roles: Dcp1a is required for decapping complex assembly and for interactions with cap-binding proteins and cofactors that shape transcript “buffering,” while Dcp1b plays more specialized roles in tuning subsets of transcripts, underscoring the centrality of Dcp1a in global mRNA decay control. In oocyte maturation and early embryogenesis, maternally recruited Dcp1a and Dcp2 are synthesized from maternal mRNAs via cytoplasmic polyadenylation, phosphorylated, and used to drive large-scale degradation of maternal transcripts; interfering with Dcp1a/Dcp2 accumulation by RNAi or morpholinos reduces maternal mRNA clearance and impairs activation of the zygotic genome, demonstrating that Dcp1a-mediated decapping is essential for the transition from mRNA stability to instability and for successful oocyte-to-zygote conversion. Dcp1a also participates in signal transduction: its amino-terminal domain can activate protein kinase R (PKR), inducing translational arrest and linking mRNA decay factors to stress-response pathways, and it contributes to TGF‑β1–dependent transcriptional responses by supporting transactivation of target genes after TGFB1 stimulation.

References
https://pubmed.ncbi.nlm.nih.gov/23136299/ https://pubmed.ncbi.nlm.nih.gov/23085078/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%